TY  - JOUR
AU  - Gimbel, Ronald W
AU  - Rennert, Lior M
AU  - Crawford, Paul
AU  - Little, Jeanette R
AU  - Truong, Khoa
AU  - Williams, Joel E
AU  - Griffin, Sarah F
AU  - Shi, Lu
AU  - Chen, Liwei
AU  - Zhang, LingLing
AU  - Moss, Jennie B
AU  - Marshall, Robert C
AU  - Edwards, Karen W
AU  - Crawford, Kristy J
AU  - Hing, Marie
AU  - Schmeltz, Amanda
AU  - Lumsden, Brandon
AU  - Ashby, Morgan
AU  - Haas, Elizabeth
AU  - Palazzo, Kelly
PY  - 2020
DA  - 2020/5/26
TI  - Enhancing Patient Activation and Self-Management Activities in Patients With Type 2 Diabetes Using the US Department of Defense Mobile Health Care Environment: Feasibility Study
JO  - J Med Internet Res
SP  - e17968
VL  - 22
IS  - 5
KW  - mHealth
KW  - diabetes mellitus
KW  - patient activation
KW  - patient-centered care
KW  - eHealth
AB  - Background: Past mobile health (mHealth) efforts to empower type 2 diabetes (T2D) self-management include portals, text messaging, collection of biometric data, electronic coaching, email, and collection of lifestyle information. Objective: The primary objective was to enhance patient activation and self-management of T2D using the US Department of Defense’s Mobile Health Care Environment (MHCE) in a patient-centered medical home setting. Methods: A multisite study, including a user-centered design and a controlled trial, was conducted within the US Military Health System. Phase I assessed preferences regarding the enhancement of the enabling technology. Phase II was a single-blinded 12-month feasibility study that randomly assigned 240 patients to either the intervention (n=123, received mHealth technology and behavioral messages tailored to Patient Activation Measure [PAM] level at baseline) or the control group (n=117, received equipment but not messaging. The primary outcome measure was PAM scores. Secondary outcome measures included Summary of Diabetes Self-Care Activities (SDSCA) scores and cardiometabolic outcomes. We used generalized estimating equations to estimate changes in outcomes. Results: The final sample consisted of 229 patients. Participants were 61.6% (141/229) male, had a mean age of 62.9 years, mean glycated hemoglobin (HbA1c) of 7.5%, mean BMI of 32.7, and a mean duration of T2D diagnosis of 9.8 years. At month 12, the control group showed significantly greater improvements compared with the intervention group in PAM scores (control mean 7.49, intervention mean 1.77; P=.007), HbA1c (control mean −0.53, intervention mean −0.11; P=.006), and low-density lipoprotein cholesterol (control mean −7.14, intervention mean 4.38; P=.01). Both groups showed significant improvement in SDSCA, BMI, waist size, and diastolic blood pressure; between-group differences were not statistically significant. Except for patients with the highest level of activation (PAM level 4), intervention group patients exhibited significant improvements in PAM scores. For patients with the lowest level of activation (PAM level 1), the intervention group showed significantly greater improvement compared with the control group in HbA1c (control mean −0.09, intervention mean −0.52; P=.04), BMI (control mean 0.58, intervention mean −1.22; P=.01), and high-density lipoprotein cholesterol levels (control mean −4.86, intervention mean 3.56; P<.001). Significant improvements were seen in AM scores, SDSCA, and waist size for both groups and in diastolic and systolic blood pressure for the control group; the between-group differences were not statistically significant. The percentage of participants who were engaged with MHCE for ≥50% of days period was 60.7% (68/112; months 0-3), 57.4% (62/108; months 3-6), 49.5% (51/103; months 6-9), and 43% (42/98; months 9-12). Conclusions: Our study produced mixed results with improvement in PAM scores and outcomes in both the intervention and control groups. Structural design issues may have hampered the influence of tailored behavioral messaging within the intervention group. Trial Registration: ClinicalTrials.gov NCT02949037; https://clinicaltrials.gov/ct2/show/NCT02949037 International Registered Report Identifier (IRRID): RR2-10.2196/resprot.6993 
SN  - 1438-8871
UR  - http://www.jmir.org/2020/5/e17968/
UR  - https://doi.org/10.2196/17968
UR  - http://www.ncbi.nlm.nih.gov/pubmed/32329438
DO  - 10.2196/17968
ID  - info:doi/10.2196/17968
ER  -